recent-news

RECENT NEWS

December, 2016

Voriconazole Tablets, 50mg & 200mg, were launched by Lupin® Pharmaceuticals. Voriconazole Tablet is AB-rated to Vfend®.

December, 2016

Voriconazole for Oral Suspension, 40 mg/mL, was launched by Lupin® Pharmaceuticals. Voriconazole for Oral Suspension is AB-rated to Vfend®.

September, 2016

Dextroamphetamine Sulfate Tablets, 5mg & 10mg, were launched by Lupin® Pharmaceuticals. Dextroamphetamine Tablet is AA-rated to Barr’s Dextroamphetamine product.

August, 2016

Zolpidem Tartrate Sublingual Tablets, 1.75mg & 3.5mg, were re-launched by Lupin® Pharmaceuticals. Zolpidem Sublingual Tablet is AB-rated to Intermezzo®.

June, 2016

Lupin® Pharmaceuticals recalls Zolpidem Tartrate Blister Packs due to risk of child poisoning. To see the Recall Announcement, please click here.

March, 2016

Lupin® Pharmaceuticals completed its acquisition of GAVIS® Pharmaceuticals LLC and Novel Laboratories Inc in the United States on March 09, 2016. To see the Press Release, please click here.

March, 2016

Zolpidem Tartrate Sublingual Tablets, 1.75mg & 3.5mg, were launched by GAVIS® Pharmaceuticals. Zolpidem Sublingual Tablet is AB-rated to Intermezzo®.

January, 2016

Fluocinolone Acetonide Topical Solution USP, 0.01%, was launched by GAVIS® Pharmaceuticals. Fluocinolone Topical Solution is AT-rated to Synalar®.

January, 2016

Methylphenidate Hydrochloride Tablets, 5mg, 10mg & 20mg, were launched by GAVIS® Pharmaceuticals. Methylphenidate Tablet is AB-rated to Ritalin®.

December, 2015

Dexmethylphenidate Hydrochloride Tablets, 2.5mg, 5mg & 10mg, were launched by GAVIS® Pharmaceuticals. Dexmethylphenidate Tablet is AB-rated to Focalin®.

November, 2015

Metoclopramide Hydrochloride Orally Disintegrating Tablets, 10mg, was launched by GAVIS® Pharmaceuticals. Metoclopramide is AB-rated to Metozolv ODT®.

AUGUST, 2015

Methylphenidate Oral Solution, 5mg/5ml & 10mg/5ml, were launched by GAVIS® Pharmaceuticals. Methylphenidate Oral Solution is AA-rated to Methylin®.

JULY, 2015

GAVIS® Pharmaceuticals has recently introduced 5 new products to the market, providing a broad range of important choices to pharmacists, prescribers and patients. The Product Announcement File can be downloaded here.

JULY, 2015

Doxycycline Capsule USP, 50mg, 75mg & 100mg, were launched by GAVIS® Pharmaceuticals. Doxycycline is AB-rated to Monodox®.

JULY, 2015

Oxycodone Hydrochloride Oral Solution USP, 100 mg/5 mL, was launched by GAVIS® Pharmaceuticals. Oxycodone Hydrochloride is AA-rated to Lehigh Valley’s product.

JULY, 2015

GAVIS® Pharmaceuticals launched GaviLyteTM website www.gavilyte.com. The press release can be downloaded here.

JUNE, 2015

Metoclopramide Hydrochloride Orally Disintegrating Tablets, 5mg, was launched by GAVIS® Pharmaceuticals. Metoclopramide is AB-rated to Metozolv ODT®. The press release can be downloaded here.

MAY, 2015

Nitrofurantoin Oral Suspension, 25mg/5mL, was launched by GAVIS® Pharmaceuticals. Nitrofurantoin is AB-rated to Furadantin®.

APRIL, 2015

GaviLyteTM-H and Bisacodyl Delayed-release Tablet was launched by GAVISTM Pharmaceuticals. GaviLyteTM-H with 2-liter volume PEG-3350 and 1 Bisacodyl tablet compares to HalfLytely®.

APRIL, 2015

Methylphenidate Chewable Tablets, 2.5mg, 5 mg & 10 mg, were launched by GAVIS® Pharmaceuticals. Methylphenidate Chewable is AB-rated to Methylin®.

MARCH, 2015

Amlodipine & Valsartan Tablets, 5/160mg, 5/320mg, 10/160mg & 10/320mg, were launched by GAVIS® Pharmaceuticals. Amlodipine & Valsartan is AB rated to Exforge®.

NEWS ARCHIVE

capabilities-recent-news-right